This study is testing a new schedule for giving a medicine called **Lutetium 177 Lu PSMA RLT** to patients with **advanced prostate cancer**. Prostate cancer is when cells in the prostate grow uncontrollably. The medicine is usually given to patients every 6 weeks, but researchers want to see if waiting longer between doses is just as effective and maybe even better for patients' quality of life. This study is for men whose cancer doesn't respond to hormone treatments and has spread to other parts of the body. **PSMA** stands for *Prostate-Specific Membrane Antigen*, a protein found on cancer cells. The medicine sticks to this protein, delivers radiation, and kills the cancer cells. **Key Points:** - **Duration & Visits:** The study involves several cycles of treatment and regular check-ups. - **Compensation:** Details on compensation are not provided, but participation may include monitoring of health and potential benefits from the treatment. - **Potential Risks:** As with any treatment, there could be side effects or risks, which will be monitored throughout the study. Patients must meet certain health criteria to join, like having a specific PSA level and a good performance status. The study will follow participants for up to 5 years to monitor their health. Learn more about eligibility and participation by contacting the study team.